Matthew Parris
Chief Tech/Sci/R&D Officer chez TRAWS PHARMA, INC.
Profil
Matthew Parris is currently working as the Vice President-Clinical Operations at Traws Pharma, Inc. He previously worked as the Director-Clinical Operations at Aegerion Pharmaceuticals, Inc. and Inovio Pharmaceuticals, Inc. He also held the position of Vice President-Clinical Development at Eleison Pharmaceuticals, Inc. Mr. Parris completed his undergraduate degree at Imperial College London.
Postes actifs de Matthew Parris
| Sociétés | Poste | Début |
|---|---|---|
| TRAWS PHARMA, INC. | Chief Tech/Sci/R&D Officer | 01/08/2018 |
Anciens postes connus de Matthew Parris
| Sociétés | Poste | Fin |
|---|---|---|
Eleison Pharmaceuticals, Inc.
 Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | Corporate Officer/Principal | - |
| AEGERION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| INOVIO PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formation de Matthew Parris
| Imperial College London | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| TRAWS PHARMA, INC. | Health Technology |
| INOVIO PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Eleison Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | Health Technology |
